Background A cough that remains unresolved for longer than 8 weeks is referred to as chronic cough, and it is estimated that 10% of the adult population of the world suffers from chronic cough. Gefapixant is a purinergic receptor P2x3 receptor antagonist. P2x3 receptors are ATP-gated ion channels on the peripheral sensory C fibers in the airways. Objective We conducted a systematic review and meta-analysis of RCTs to investigate whether the chronic cough patients would benefit from gefapixant administration or not when compared to placebo. Methods We selected only those double-arm randomized controlled trials (RCTs) which included participants presenting with a chronic cough in patients 18 years or older. We excluded all the articles published in languages other than English Language. Furthermore, all the studies other than RCTs were also omitted. Articles yielded from the electronic search were exported to EndNote Reference Library software to remove any duplicates. Analyses were done using the Review Manager 5.4 tool. Mean values and standard deviations were retrieved for the continuous outcomes given as raw data. Results 8 RCTs selected for the statistical analysis consisted of 2024 participants (1011 in the intervention group and 1013 in the placebo group). The outcomes resulted to be significant with 24-hour cough frequency, the mean difference [MD] = -5.26, 95% confidence interval [CI] -7.18 to -3.33; p = 0.00001; n = 3518, awake cough frequency (c/h) [MD] = -6.78, 95% confidence interval [CI] -9.46 to -4.09; p = 0.00001; n = 3472 patients., night cough frequency (c/h) [MD] = -4.07, 95% confidence interval [CI] -5.49 to -2.65; p = 0.00001; n = 479, patients cough severity VAS (mm) [MD] = -14.84, 95% confidence interval [-19.92, -9.76], p = 0.00001, n= 1297, cough severity diary difference [MD] = -0.85; 95% confidence interval [CI]: -1.14, -0.56; p-value = 0.00001; n = 1219, Total LCQ score MD=2.04, 95% CI = 1.09 to 2.98, p<0.0001, n =869. Conclusion To conclude, the lowest efficacious dose was 50 mg twice daily and helped reduce 24-hour cough frequency, awake cough frequency, night cough frequency, and cough severity using VAS in a dose-dependent manner. Gefapixant showed a significant risk of adverse events which include dysgeusia, hypogeusia, nausea, any adverse event, taste-related and drug-related adverse events, and serious AEs

AIMS:Approximately 55% of patients diagnosed with primary or metastatic cancer endure pain directly attributable to the disease. Consequently, it becomes imperative to address pain management through a comparative analysis of stereotactic radiotherapy (SRT) and conventional radiation therapy (CRT), especially in light of the less efficacious improvement achieved solely through pharmacological interventions. MATERIALS AND METHODS:A systematic exploration was undertaken on PubMed, the Cochrane Library, and Elsevier's ScienceDirect databases to identify studies that compare Stereotactic Radiotherapy to Conventional radiation therapy for pain management in individuals with metastatic bone cancer. The analyses were executed utilizing the random-effects model. RESULTS:A cohort of 1152 participants with metastatic bone cancer was analyzed, demonstrating significantly higher complete pain relief in the Stereotactic Radiotherapy group during both early and late follow-up (RR: 1.61; 95% CI: 1.17, 2.23, p-value: 0.004; I2: 0%). Stereotactic Radiotherapy also showed a non-significant increase in the incidence of partial pain relief (RR: 1.07; 95% CI: 0.85, 1.34, p-value: 0.56; I2: 18%). Furthermore, Stereotactic Radiotherapy was associated with a significantly reduced risk of stationary pain throughout follow-up (RR: 0.61; 95%CI: 0.48, 0.76, p-value: <0.0001; I2: 0. The incidence of progressive pain was non-significantly reduced with Stereotactic Radiotherapy during both early and late follow-up (RR: 0.77; 95% CI: 0.50, 1.17, p-value: 0.22; I2: 0%). Secondary outcomes exhibited a non-significant trend favoring Stereotactic Radiotherapy for dysphagia, esophagitis, pain, and radiodermatitis, while a non-significant increase was observed for nausea, fatigue, and vertebral compression fracture. CONCLUSION:In summary, stereotactic radiation therapy (SRT) has improved in achieving complete pain relief while exhibiting a decreased probability of delivering stationary pain compared to conventional radiation therapy (CRT). Nevertheless, it is crucial in future research to address a noteworthy limitation, specifically, the risk of vertebral compression fracture.

Vitamin D plays a vital role in health; therefore, there is a need for a sensitive, selective, quick, and easy technique for its determination. Previous research has proposed electrochemical biosensors based on different carbon materials that are functionalized with various electrochemical biosensors. However, the existing problems and future opportunities for these sensors need further research. The practical use of electrochemical biosensors for vitamin D detection is attributed to their ability to detect vitamin D from diverse samples, including vitamin D production, in nature. This chapter provides recent investigations on the utilization of electrochemical biosensors for vitamin D detection such as Ab-25OHD/SPE/FMTAD, CYP27B1/GCE, SiO2/GO/Ni(OH)2/GCE, BSA/Ab-VD2/CD-CH/ITO, BSA/Anti VD/Fe3O4 PANnFs/ITO, BSA/Ab-VD/Asp-Gd2O3NRs/ITO, 25OHD, 25OHD Antibody, IoT-Enabled Enzyme Embossed Biosensor, Au-Pt NPs/APTES/FTO, and GCN-β-CD/Au nanocomposite. The chapter aims to provide a comprehensive overview of the recent developments in electrochemical biosensors for accurate and efficient vitamin D detection.

Currently, cancer ranks as the second leading cause of death worldwide, and at the same time, the burden of cancer continues to increase. The underlying molecular pathways involved in the initiation and development of cancer are the subject of considerable research worldwide. Further understanding of these pathways may lead to new cancer treatments. Growing data suggest that Tribble's homolog 3 (TRIB3) is essential in oncogenesis in many types of cancer. The mammalian tribbles family's proteins regulate various cellular and physiological functions, such as the cell cycle, stress response, signal transduction, propagation, development, differentiation, immunity, inflammatory processes, and metabolism. To exert their activities, Tribbles proteins must alter key signaling pathways, including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/AKT pathways. Recent evidence supports that TRIB3 dysregulation has been linked to various diseases, including tumor development and chemoresistance. It has been speculated that TRIB3 may either promote or inhibit the onset and development of cancer. However, it is still unclear how TRIB3 performs this dual function in cancer. In this review, we present and discuss the most recent data on the role of TRIB3 in cancer pathophysiology and chemoresistance. Furthermore, we describe in detail the molecular mechanism TRIB3 regulates in cancer.

Background Cystic fibrosis (CF) is a genetic disorder with diverse symptoms. Understanding its genetic basis and prevalence is crucial for effective management and treatment. Objective The study aimed to provide comprehensive insights into the frequency of CF gene mutations, clinical presentations, and complications among the Pakistani population. Methodology A cohort comprising 892 patients, ranging in age from 18 to more than 40 years, was selected on the basis of clinical and genetic criteria for the diagnosis of CF. Polymerase chain reaction (PCR) was used to look for 34 variants in the CFTR gene in blood samples. Statistical analysis, which included figuring out the number of mutations, the average age of diagnosis, and the genetic diversity of the samples, was performed to analyze the percentage of patients with specific mutations, offering insights into the genetic diversity. Results In our comprehensive analysis of 892 patient samples, 77.47% (n=691) displayed consanguinity, indicating a family history. The prevailing symptoms included chronic cough (88.67%; n=791), recurrent respiratory infections (76.68%; n=684), and fatigue (73.76%; n=658). The major complications comprised pulmonary infections (22%; n=197), cystic fibrosis-related diabetes (21%; n=187), and malabsorption (20%: n=178). A paired t-test revealed a mean difference of 5.750 with a standard deviation of 9.147, a 95% confidence interval from -0.061 to 11.561, a t-value of 2.178 with 11 degrees of freedom, and a two-tailed p-value of 0.052, suggesting a potential trend towards significance. Nevertheless, the asymptotic significance values of 1.000 and 0.998 for both groups indicate no significant difference. Furthermore, the study identified 12 cystic fibrosis gene mutations, with F508del and N1303K being the most prevalent. Conclusion This research revealed significant consanguinity, confirmed typical CF symptoms, and identified common complications and prevalent CFTR gene mutations (with F508del and N1303K being the most common), providing insights for genetic guidance and treatment in the Pakistani community.

The research looks at access to the radial artery in contemporary medicine to lower the occurrence of acute kidney injury (AKI). In an effort to increase patient-centered procedural safety, it evaluates evidence contrasting radial versus femoral access. Objective: To determine if access to the radial artery and the prevalence of AKI during interventional procedures, with an emphasis on evaluating the possible advantages of radial access in lowering the risk of AKI. Methods: An examination of 132 instances classified by access location (radial artery as opposed to other sites) was done retrospectively. Beginning in September 2022 and ending in March 2023, the study's length was six months. AKI incidence, procedure specifics, and demographic data were compared. The independent influence of radial access on the risk of AKI was evaluated using multivariate logistic regression. Results: The radial artery group (13.6%) exhibited a significantly lower AKI incidence than the comparator group (27.3%). Multivariate analysis confirmed the independent association. Conclusions: The possible relevance of access to the radial artery in reducing post-procedural AKI highlights the possibility of a safer alternative. Evidence-based access site selection is becoming more crucial in the age of patient-centered healthcare to improve procedural outcomes.

Background: Although chemotherapy and radiotherapy are effective in cancer treatment, different adverse effects induced by these therapeutic modalities (such as ototoxicity) restrict their clinical use. Co-treatment of melatonin may alleviate the chemotherapy/radiotherapy-induced ototoxicity. Objective: In the present study, the otoprotective potentials of melatonin against the ototoxicity induced by chemotherapy and radiotherapy were reviewed. Methods: According to the PRISMA guideline, a systematic search was carried out to identify all relevant studies on "the role of melatonin against ototoxic damage associated with chemotherapy and radiotherapy" in the different electronic databases up to September 2022. Sixty-seven articles were screened based on a pre-defined set of inclusion and exclusion criteria. Seven eligible studies were finally included in this review. Results: The in vitro findings showed that cisplatin chemotherapy significantly decreased the auditory cell viability compared to the control group; in contrast, the melatonin co-administration increased the cell viability of cisplatin-treated cells. The results obtained from the distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) tests demonstrated a decreased amplitude of DPOAE and increased values of ABR I-IV interval and ABR threshold in mice/rats receiving radiotherapy and cisplatin; nevertheless, melatonin co-treatment indicated an opposite pattern on these evaluated parameters. It was also found that cisplatin and radiotherapy could significantly induce the histological and biochemical changes in the auditory cells/tissue. However, melatonin co-treatment resulted in alleviating the cisplatin/radiotherapy-induced biochemical and histological changes. Conclusion: According to the findings, it was shown that melatonin co-treatment alleviates the ototoxic damage induced by chemotherapy and radiotherapy. Mechanically, melatonin may exert its otoprotective effects via its anti-oxidant, anti-apoptotic, and anti-inflammatory activities and other mechanisms.

INTRODUCTION:A frequent medical procedure to accelerate labor is the induction of labor. There are different methods of labor induction, including the use of medications such as misoprostol, oxytocin, and dinoprostone.OBJECTIVE:This research compared the effectiveness and safety of oral misoprostol, intravenous oxytocin, and intravaginal dinoprostone for labor induction in Pakistani women.METHODOLOGY:A study was conducted in the Department of Obstetrics and Gynaecology, Hayatabad Medical Complex-Medical Teaching Institute (MTI) and Lady Reading Hospital-MTI, Peshawar, Pakistan, over two years. It included 378 women between 38 and 42 gestational weeks, divided into three groups of 126 women each. The oral misoprostol group was given a maximum of six doses of a 25 μg oral misoprostol solution (oral misoprostol tablet of 200 μg dissolved in 200 ml) at intervals of two hours. The drip rate for the intravenous oxytocin group ranged from 6 mIU/minute to 37 mIU/minute. The intravaginal dinoprostone group received a controlled-release vaginal insert containing 10mg of intravaginal dinoprostone, which was left in place for 12 hours.RESULTS:More women in the oral misoprostol group (n=94; 74.6%) had successful inductions when compared to the intravaginal dinoprostone (n=83; 65.9%) and intravenous oxytocin (n = 77; 64.71%) groups. Oral misoprostol had the greatest proportion of normal vaginal deliveries (n=62; 65.95%), followed by intravaginal dinoprostone (n=47; 56.63%), and intravenous oxytocin had the lowest rate (n=33; 42.85%). Cesarean section rates were greatest in the intravenous oxytocin group (n=31; 40.26%), followed by the intravaginal dinoprostone group (n=29; 34.94%), and lowest in the oral misoprostol group (n=24; 25.53%).CONCLUSION:Oral misoprostol induces labor in women safely and effectively, resulting in the lowest percentage of cesarean deliveries and the highest percentage of normal vaginal deliveries, respectively. Intravaginal dinoprostone showed the lowest rate of side effects, followed by oral misoprostol while intravenous oxytocin had the highest rate of side effects.

I request you to note that this is a letter. Thanks to CPC, which already accepted our earlier letter.